Cue Biopharma, Inc.

The call did not provide revenue, EPS, gross margin, or other standard quarterly financial metrics. On the clinical side, management said CUE-101 combination therapy in first-line recurrent/metastatic HPV+ head and neck cancer produced an objective response rate of 46% in CPS >= 1 patients, including 10 confirmed partial responses and 1 confirmed complete response among 24 evaluable patients. In CPS 1-19 patients, ORR was 50%; median PFS was 5.8 months; 12-month OS was 90%; and median OS was 21.8 months. In CPS >= 20 patients, 12-month OS was 100% and median OS had not yet been reached. For CUE-101 monotherapy in the second line-plus setting, median OS was 24.8 months at 2 mg/kg and 20.8 months at 4 mg/kg. Management also cited historical comparator figures from KEYNOTE-048 and checkpoint inhibitor benchmarks, including pembrolizumab monotherapy ORR of 19%, 12.3-month median OS, and 51% 12-month OS in CPS >= 1 patients. For CUE-102, management said no DLTs had been observed and that patients remained on treatment or active follow-up. Forward-looking guidance included CUE-401 lead candidate selection in Q1 of the coming year, additional CUE-101/CUE-102 updates at CITC in November, runway to mid-2025, and burn reduced to about $30 million per year.

Dan Passeri framed the quarter around a strategic reset: reduce capital needs, let oncology data mature, and lean into partnerships to fund autoimmune development. He said the company believes its platform can restore immune balance in cancer and autoimmune disease, and described CUE-101 survival data as potentially supportive of a new standard of care. His tone was measured but optimistic, with repeated emphasis on partnering, prudence, and preserving optionality while avoiding highly dilutive financing.

No formal CFO remarks were provided, but management gave financial detail during the prepared remarks and Q&A. Dan Passeri said the company extended runway to mid-2025 and reduced annual cash burn from about $40 million to about $30 million per year. He said partnering could bring upfront and milestone payments plus sponsored FTE support to further lower burn, and stressed the company is aiming to keep dilution minimal and any future capital raise modest if needed.

Analysts focused heavily on CUE-501 trafficking, CMV positivity, and whether the program would need screening in a Phase 1 study; Anish Suri said CMV positivity is roughly 65% to 70%, noted the platform can also use other viral epitopes, and said Immuno-STATs have shown tissue penetration in prior imaging work. Questions also probed whether better-matured survival data could attract strategic interest for CUE-101; Passeri said partners are already watching the data and that survival should be more dispositive than response rates alone. On the financial side, management explained that 401 milestones with Ono and a potential 501 partnership are intended to bridge the company to later milestones without a large dilutive raise.